Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVB-2640 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Sagimet Biosciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TVB-2640 + chemotherapy refers to the combination of **TVB-2640**, a first-in-class, orally available, selective small molecule inhibitor of **fatty acid synthase (FASN)**, with various chemotherapeutic agents. TVB-2640 acts by **blocking de novo lipogenesis** (DNL) in tumor cells, thereby reducing steatosis and interfering with the metabolic support cancers need to grow and survive, especially under hypoxic conditions. It is under investigation for a range of solid tumors. In clinical trials, TVB-2640 has most frequently been combined with chemotherapies such as **bevacizumab** (an anti-VEGF monoclonal antibody) and **paclitaxel** (a taxane), as well as with other agents like **enzalutamide** (for prostate cancer) and **SN-38** (the active metabolite of irinotecan). The combination is in **phase I/II trials** for high-grade astrocytoma/glioblastoma, solid tumors, triple-negative breast cancer, and metastatic castration-resistant prostate cancer, among others. Developer and manufacturer have overlapping roles and include Sagimet Biosciences. TVB-2640 is not approved by the FDA or other major regulatory agencies for any indication as of late 2025[1][4][7][9].
- Brand names
- denifanstat
- Other names
- TVB-2640 + chemotherapy
02
Targets
FASN (Fatty acid synthase)
Beyond the preview
Go deeper on TVB-2640 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVB-2640 + chemotherapy.